The Recurrence of Cervical Precancerous Lesion Among HIV Positive and Negative Ethiopian Women After Cryotherapy: A Retrospective Cohort Study

Agajie Likie Bogale, MSc1,2, Tilahun Teklehaymanot, PhD2, Jemal Haidar Ali, MD, MSc, CME, HD, Getnet Mitike Kassie, MD, PhD, and Girmay Medhin, PhD2

Abstract

Background: Early testing and treatment is among the successful strategies for the prevention and control of cervical precancerous and invasive cancer, and a paramount for women with HIV. In Ethiopia, visual inspection with acetic acid for screening and cryotherapy treatment is commonly practiced, though the recurrence of the precancerous lesion after treatment has not been well documented.

Objective: This study was aimed to estimate the association of HIV status and the recurrence of cervical precancerous lesion after cryotherapy among Ethiopian women.

Methods: We conducted a retrospective cohort study from January to April 2021. The time to the incidence of recurrence was compared between HIV positive and HIV negative women. Cox regression models were used to adjust the analyses for potential confounders, and only women treated with cryotherapy after a positive Visual Inspection with Acetic acid (VIA) screening test were included.

Results: A total of 140 eligible patient cards were included in the analysis with the median follow-up of 15.5 months. The overall recurrence rate was 15.7% (22/140), with a greater proportion among HIV negative women, 19.0% (4/21) than HIV positive 15.1% (18/119). Prolonged use of corticosteroid and higher age were the major significant predictors of a higher likelihood of recurrence. The recurrence of screening positive lesion was higher among women aged above 39 years (hazard ratio (HR) of 11.94 (95% CI, 1.07-133.04; P = .04), and women with prolonged use of corticosteroid (HR = 7.82, 95% CI = 1.04-58.75; P = .046) than their counterparts.

Conclusion: The recurrence of cervical precancerous lesion after cryotherapy was higher than the expert panel report by WHO with a higher proportion among women of old age and prolonged corticosteroid use. Cryotherapy showed a satisfying performance against the recurrence of cervical disease diagnosed through VIA. To substantiate, our findings, further prospective cohort study is also recommended.

Keywords
visual inspection with acetic acid, cryotherapy, recurrence, women, Ethiopia

Introduction

Despite comprehensive approach to cervical cancer prevention and control strategy implemented globally,1 the high morbidity and mortality due to the disease is alarming, predominantly in African countries.2 Furthermore, despite the theoretical framework from cervical cancer screening
and control—these strategies are not often well implemented in low to middle income countries with coverage often being very low. According to the estimate of Global Cancer Observatory 2020 database (GLOBOCAN 2020), the incidence of cancer of the cervix uteri was 604,127, with 341,831 deaths worldwide. Compared with the 2018 estimate (ie, 311,365 women’s deaths) worldwide, the trend of death is increasing, although it is a rare disease in countries with strong screening programs. In Ethiopia, new cases and deaths of cervix uteri were 7445 and 5338, respectively (GLOBOCAN 2020). The disease (invasive cervical cancer) is caused by the sexually transmitted high-risk human papillomavirus types (HPVs), with other risk factors, including Human Immunodeficiency virus (HIV), driving infection.

The recurrence of cervical precancerous lesion was higher among HIV infected women as compared to women without HIV (18.3% vs 12.3%), though the difference was not statistically significant. The magnitude of relapse among treated patients ranges between 11% to 64%. According to the WHO 2011 report, expert panels strongly recommend cryotherapy over no treatment and the recurrence rate of all cervical intraepithelial neoplasia was reported as 6%. The average age of women with cervical carcinoma recurrence was about 40-45 years and the majority of recurrence occurs within 18-24 months from the time of diagnosis. Expert reviews also indicated that metastatic or recurrent cervical cancer has a survival duration of approximately 12 months.

Although the Federal Ministry of Health in Ethiopia has adopted the guideline for cervical cancer prevention and control in 2015, and has been implementing VIA for screening and cryotherapy for treatment, though evidences regarding recurrence of cervical precancerous lesion after treatment and the performance of the methods is lacking. Therefore, this study was aimed to estimate the proportion of women that encountered recurrence of cervical neoplasia after the initiation of treatment and to investigate factors associated with recurrence in order to help in designing of the appropriate patient management strategies in the country.

**Materials and Methods**

**Study Design**

We conducted a retrospective cohort study of women with known HIV status who have been screened for cervical precancerous lesion and treated at the same visit with cryotherapy. The reporting of this study conforms to STROBE guidelines.

**Study Setting and Period**

This study was conducted from the 2 centers of excellence, namely Zewdu Memorial Hospital and St Paul’s Hospital, which are public hospitals in Addis Ababa, Ethiopia, from January to April 2021. Addis Ababa is the capital of Ethiopia, and geographically located at the center of Ethiopia, at 9°14’48”N38°44’24”E, with an approximate land area of 526.46 square km. The location of data collection sites was as follows: The Zewdu Memorial Hospital is located in the Kirkos sub-city and St Paul’s Hospital is located in the Gulele sub-city, which are among a total of 11 sub-cities in the Addis Ababa city. The 2 hospitals were selected for the current study based on their client load and high HIV testing, treatment and follow-up services, in addition to their involvement in early initiation of cervical cancer screening with an average of 10 years cervical screening experience. All eligible patient cards that met the specified objective were included as our study subjects.

**Sample Size Estimation**

The required sample size was estimated using observational study formula initially, considering the HIV positive women as the exposed group and HIV negative women as non-exposed group, though the actual eligible data in the record were less than calculated that allow us to include all the eligible records in the study. As shown in Figure 1, a total of 5860 women were screened using VIA for the average of the 10 year period from 2009 to February 7, 2021. Out of the total screened, about 1636 patient records were excluded initially due to unknown HIV status, appointment date of treatment follow-up, which was beyond our data collection period and lack of information on the register. Of the remaining 4224 patient records, 3052 were HIV positive and 1172 HIV negatives. After checking the VIA positivity result, only 628 cases were identified, which was less than the calculated sample size (n = 1275). Of these, only 321 records were eligible for chart review. Baseline HIV status, cervical screening status and treatment of patients positive for cervical precancerous lesion were the main inclusion criteria for the current study. On the other hand, those client cards with missed information to address the proposed objective, including absence of assessment sheet in the patient card, no clear information about VIA result, first visit VIA result negative in the patient card, patients refused for cryotherapy and not eligible for this treatment, missed patient cards during the time of chart review, were excluded.

**Data Extraction**

Chart reviews were conducted by trained health professionals and the principal investigator. Data were extracted from the cervical cancer assessment sheets or history intake forms used...
Data Computerization and Analysis

Data were entered into an excel spreadsheet, exported and analyzed using SPSS version 25. Proportional hazards assumption test (phtest) was checked using STATA version 14. Descriptive statistical methods were used to summarize participants’ characteristics of the study. Quantitative variables like the Body Mass Index (BMI) were categorized based on clinical implication. We run Kaplan Meier to estimate a survival distribution and the results were reported using a Log Rank test. The proportional hazard model was used to estimate the effect of HIV status and the other predictor variables on the time to the recurrence of cervical precancerous lesions after treatment using cryotherapy. Hazard ratio with 95% confidence interval was reported as a measure of the strength of association between the target risk factor and the outcome of interest. The independent variables were included in a multivariate analysis provided that $P$-value was less than .25 in the univariate analysis, and sensitivity analysis was done.

Operational Definition

- Recurrence in this study refers to the relapse or re-infection of women who had treatment for cervical precancerous lesion.
- Cryotherapy refers to a procedure, which involves freezing an area of abnormal tissue on the cervix and the tissue gradually disappears and the cervix heals. The procedure is based on the WHO expert panel suggestions to apply double freeze using a 3 minute freeze, 5 minute thaw, 3 minute freeze cycle over single-freeze cryotherapy using carbon dioxide gas.
- Survival time refers to the time from a woman’s diagnosis of cervical precancerous lesion and cryotherapy treatment until the time of the recurrence of the lesion.
- Corticosteroids are a type of anti-inflammatory drug used to treat rheumatologic diseases, lupus or vasculitis, etc.

Ethical Considerations

Ethical approval for the study was obtained from Addis Ababa University, Aklilu Lemma Institute of Pathobiology, IRB (ALIPB-IRB/35/2013/21) and a further facility-based ethical approval was obtained from the City Government of Addis Ababa Health Bureau (A/A/H/60922/227) and St Paul’s Hospital, Millennium Medical College (SPHHMC-IRB/PW/23/398).
The objectives of the study were well explained to all concerned bodies and permission was obtained from selected health facilities to collect data. No consent was taken for this particular study, since we conducted a chart review with no direct patient contact. All information obtained from chart review was kept confidential. Names or personal identifiers were not included in the study, meaning, all the patient details were de-identified. To trace back participant information, medical record number and serial number found in the eligible patient card was used.

**Results**

In this study, only 61.8% of patient records were eligible for inclusion at baseline/enrolment (denoted as visit 0 in Figure 2). Less than a third of patients (27.9%) returned for their first annual follow-up visit after cryotherapy (denoted as visit 1 in Figure 2). Of those 145 patient records, five records were excluded due to the fact that 3 follow-up results indicated suspicious for cancer, which was beyond cryotherapy treatment, 1 record was with unknown status of the first follow-up and additional 1 due to lack of date of follow-up to calculate months of follow-up. Thus, only 140 records were included in the analysis.

The mean age of eligible patients was 35.06 (SD = 5.3) with the minimum and the maximum age of 20 and 55 years, respectively. Sixty 1 participants (43.6%) were in the age range of 30 to 34 years. Of the total study participants, 14 (10%) did not report the age at first intercourse. Of those who reported the age of the first intercourse, the youngest age was

![Figure 2. Percentage of women who visit Zewditu memorial hospital and St. Paul hospital for screening and treatment of cervical precancerous lesion. On the x-axis, zero indicates those women who were initial screening positive using VIA and treated using cryotherapy, and 5 is the maximum follow-up observed in the study. The y-axis indicated the percentage of each follow-up visit.](image)

### Table 1. Demographic characteristics of eligible patient records of the earliest cervical cancer screening Hospitals in Addis Ababa, Ethiopia, January to April, 2021.

| Characteristics                  | Number | Percentage |
|----------------------------------|--------|------------|
| **Age in years**                 |        |            |
| 20-24                            | 3       | 2.1        |
| 25-29                            | 3       | 2.1        |
| 30-34                            | 61      | 43.6       |
| 35-39                            | 47      | 33.6       |
| ≥40                              | 26      | 18.6       |
| **Age at the first intercourse** |        |            |
| <18 years                        | 50      | 39.7       |
| ≥18 years                        | 76      | 60.3       |
| **Educational level**            |        |            |
| No formal education              | 7       | 5.8        |
| Elementary school                | 36      | 29.8       |
| High school                      | 71      | 58.7       |
| College or university            | 7       | 5.8        |
| **Marital status**               |        |            |
| Unmarried                        | 9       | 6.7        |
| Married                          | 77      | 57.0       |
| Divorced                         | 24      | 17.8       |
| Widowed                          | 25      | 18.5       |
| **Parity**                       |        |            |
| Nulliparity                      | 17      | 12.5       |
| Low multiparity (1 to 3)         | 101     | 74.3       |
| Grand multiparity (4 to 8)       | 18      | 13.2       |

The sample size doesn’t add up to 140 due to exclusion of missing data except the age.
11 years while the maximum year of the first intercourse was 30 years with the mean age of 18.6 (SD = 3.6). Among these, 50 (39.7%) were under 18 years of age when they experienced first intercourse. More than half of the participants (58.7%) have high school level of education and (57.0%) were married. Nearly three-fourth (74.3%) had low multiparity (1 to 3) births [Table 1].

Thirty-three (29.5%) women’s records indicated contraceptive use for birth control. Forty (31.0%) had irregular bleeding pattern. More than 1 sexual partner of the clients and the spouse was observed among 73 (60.3%) and 47 (58.8%) of the study participants, respectively. More than one third of clients (38.0%) and at least one fourth (22.9%) of the partners had a history of sexually transmitted infection (STI). History of smoking, abnormal Pap history, prolonged corticosteroid use and abnormal pelvic examination were observed in 8.6%, 5.1%, 5.0%, 5.8% women, respectively. The majority (85.0%) of women included in the study were HIV positive. More than half (58.8%) of the participants had healthy weight and the mean BMI was 23.2 kg/m$^2$ (SD = 4.2). The majority (81.4%) of patient records indicated that their CD4 value was higher than 350 cells/mm$^3$ [Table 2], indicating that patients on Antiretroviral therapy (ART) had good adherence.

### Table 2. Behavioral and clinical characteristics of eligible patient records of the earliest cervical cancer screening Hospitals in Addis Ababa, Ethiopia, January to April, 2021.

| Characteristics                          | Number | Percentage |
|------------------------------------------|--------|------------|
| Contraceptive use                         |        |            |
| No                                       | 79     | 70.5       |
| Yes                                      | 33     | 29.5       |
| Bleeding pattern                         |        |            |
| Regular                                  | 76     | 58.9       |
| Irregular                                | 40     | 31.0       |
| Menopause                                | 13     | 10.1       |
| History of STI client                    |        |            |
| No                                       | 80     | 62.0       |
| Yes                                      | 49     | 38.0       |
| History of STI partner                   |        |            |
| No                                       | 74     | 77.1       |
| Yes                                      | 22     | 22.9       |
| Sexual partners of client                 |        |            |
| 0 and 1                                  | 48     | 39.7       |
| >1                                       | 73     | 60.3       |
| Sexual partners of spouse                 |        |            |
| 0 and 1                                  | 33     | 41.3       |
| >1                                       | 47     | 58.8       |
| History of smoking                       |        |            |
| No                                       | 96     | 91.4       |
| Yes                                      | 9      | 8.6        |
| History of abnormal Pap                  |        |            |
| No                                       | 94     | 94.9       |
| Yes                                      | 5      | 5.1        |
| Prolonged Corticosteroid use history     |        |            |
| No                                       | 96     | 95.0       |
| Yes                                      | 5      | 5.0        |
| HIV status                               |        |            |
| Negative                                 | 21     | 15.0       |
| Positive                                 | 119    | 85.0       |
| Pelvic Examination                       |        |            |
| Normal                                   | 97     | 94.2       |
| Abnormal                                 | 6      | 5.8        |
| BMI (kg/m$^2$)                           |        |            |
| Under weight (<18.5)                     | 11     | 11.3       |
| Healthy weight (18.5-24.9)               | 57     | 58.8       |
| Over weight (25-29.9)                    | 22     | 22.7       |
| Obese range (30-39.9)                    | 7      | 7.2        |
| CD4 Value (cells/mm$^3$)                 |        |            |
| <350                                     | 11     | 18.6       |
| ≥350                                     | 48     | 81.4       |

(For Table 2, only the second column shows the values of the characteristics and the third column shows the corresponding percentages. The sample size doesn’t add up to 140 due to exclusion of missing data.)

The rate of the recurrence of cervical precancerous lesion after cryotherapy

The rate of the recurrence of cervical precancerous lesion was 15.7% (22/140) with the median follow-up of 15.5 months. Among the total of 22 events observed, 4 events were HIV negative women, which was 19.0% (4/21), and 15.1% (18/119) of the events were HIV positive women. The longest time to the recurrence for HIV negative women was 24 months while for HIV positive women was 72 months [Figure 3(a)]. Overall comparison among HIV positive and negative women was identified using Log Rank (Mantel-Cox) and depicted that there was a significant difference between the 2 observations (Chi-Square = 6.943, DF = 1, and P-value = .008). The survival estimate using the age category, the highest survival was seen in the age category 30-34 years, indicating 72 months, followed by greater than 39 years of age that the last event happened in 59 months and 35-39 years of age in which last event observed at 46 months of follow-up [Figure 3(b)]. The test of equality of survival distribution for the different levels of age category or overall comparison couldn’t indicate a significant difference (Chi-Square = 4.092, DF = 4; P-value = .39).

Predictors of the recurrence of cervical precancerous lesion after cryotherapy

The univariate and multivariate analysis was conducted to identify the predicting variables of the recurrence. Both quantitative predictor variables like Age, CD4 count, BMI, hematological parameters such as haemoglobin, white blood cells, neutrophils and lymphocytes, and different categorical variables, including age range, marital status, educational status, parity, contraceptive use, smoking, bleeding pattern, history of STI, HIV status, etc., were included in the univariate analyses. However, only few categorical variables
met the specified eligibility requirement to apply multivariate analysis. These were HIV status (95% CI, .06-.76; P = .017), age range, BMI, bleeding pattern, Corticosteroid use, and pelvic examination. The age greater than 39 years, Corticosteroid use and abnormal pelvic examination were consistent significant predictors for the recurrence of cervical precancerous lesion after adjusting the confounders [Table 3] and a sensitivity analysis was made. For instance, HIV status was omitted on the first adjustment of confounders, and so forth. The hazard ratio of the recurrence with age group was 11.94 (95% CI, 1.07-133.04; P = .04), meaning the recurrence of infection was more likely higher among the age group older than 39 years compared with the younger population. Those women who used corticosteroid had 7.82 times more likely developed the recurrence of cervical precancerous lesion (ie, HR = 7.82, 95% CI = 1.04-58.75;
Table 3. Univariate and multivariate hazard ratio of women screened for cervical cancer in excellence sites of Addis Ababa, Ethiopia, January to April, 2021.

| Covariates                  | Univariate analysis |                      | Multivariate analysis |                      |
|-----------------------------|---------------------|----------------------|-----------------------|----------------------|
|                             | HR                  | 95%CI for HR         | HR                    | 95%CI for HR         |
|                             | Lower               | Upper                | Lower                 | Upper                |
| Age range                   |                     |                      |                       |                      |
| 20-24                       | 1                   | 1                    | 1                     | 1                    |
| 25-29                       | .000                | .000                 | 1.53                  | 1.53                 |
| 30-34                       | .18                 | .02                  | 2.22                  | 2.22                 |
| 35-39                       | .27                 | .03                  | 3.50                  | 3.50                 |
| ≥40                         | .39                 | .04                  | 11.94                 | 11.94                |
| Bleeding pattern            |                     |                      |                       |                      |
| Regular                     | 1                   | 1                    | 1                     | 1                    |
| Irregular                   | 5.65                | 2.10                 | 15.22                 | 15.22                |
| Menopause                   | 2.93                | .59                  | 14.65                 | 14.65                |
| Corticosteroid use          |                     |                      |                       |                      |
| No                          | 1                   | 1                    | 1                     | 1                    |
| Yes                         | 4.66                | 1.03                 | 21.15                 | 21.15                |
| Pelvic Examination          |                     |                      |                       |                      |
| Normal                      | 1                   | 1                    | 1                     | 1                    |
| Abnormal                    | 12.08               | 2.02                 | 72.33                 | 72.33                |
| BMI Category                |                     |                      |                       |                      |
| Healthy weight              | 1                   | 1                    | 1                     | 1                    |
| Under weight                | 2.997               | .95                  | 9.48                  | 9.48                 |
| Over weight                 | .319                | .04                  | 2.60                  | 2.60                 |
| Obese                       | 2.381               | .49                  | 11.55                 | 11.55                |

One indicates the reference category, HR = hazard ratio.

P = .046) when compared with their counterparts. In addition, those women who had an abnormal pelvic examination during the time of visit were almost eighty times more likely to develop the recurrence (ie, HR = 79.19, 95% CI = 3.51-1788.05; P = .006) [Table3].

Discussion

It was evident that post-treatment follow-up of cervical precancerous lesion recommended at 12 months to ensure treatment efficacy.15,16 We estimated the recurrence rate of cervical precancerous lesion among HIV positive and negative women in Ethiopia who were screened using VIA and treated by using cryotherapy. The key findings include: the survival analysis or time-to-event of the recurrence of cervical precancerous lesion after cryotherapy indicated 15.7% with median follow-up of 15.5 months. The highest time to recurrence was seen among HIV positive women and age category of 30-34 years (72 months each). The age greater than 39 years, Corticosteroid use and abnormal pelvic examination were found to be consistent significant predictors for the recurrence of cervical precancerous lesion.

Our study finding was higher than the 5-year recurrence rate reported for the Danish women,17 and 4.5 years, median follow-up of women in Thailand,18 which were 6.4%, and 10.3%, respectively. Compared with the previous expert review report on the recurrence rates of cervical intraepithelial neoplasia (CIN) based on evidence generated from observational studies that have used cryotherapy (6%),8 our finding varied markedly. The difference might be due to the recurrence of the previous studies reported based on the International Federation of Gynaecology and Obstetrics (FIGO) stage, and the treatment modality was not purely cryotherapy,17,18 and CIN category.8 In addition, we used women with HIV as an exposed group and pure cryotherapy treatment, which was different from the previous aforementioned studies. Meaning, the characteristics of the study population, including the widespread availability of health care, and cancer screening, in these countries might induce the observed difference. On the other hand, a study conducted among Nigerian women reported recurrence of 16.4%,6 which was somewhat closer to our finding (15.7%) though the treatment modalities employed in Nigeria was thermo-coagulation as opposed to our study which used cryotherapy. A higher proportion of the recurrence was reported among HIV positive women than HIV negatives in the previous study,6 though not statistically significant. Surprisingly, the proportion of the recurrence was higher among HIV-negative women compared with HIV-positives in our current study, although the loss-to-follow-up was high and the number of the study subjects was less among HIV-negative women to further interpret our finding. This might be due to the fact that HIV positive women are coming into the clinic frequently, and used health care services.

According to the 2016 State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer report, recurrence was described as being diagnosed within 2 years of initial treatment,19 and the percentage of pelvic recurrences fluctuates from 10 to 74%,9 which was inclusive of the current finding. The recurrence of Cervical Intraepithelial Neoplasia following treatment occurs in at least 15% of cases even with the most effective excision and ablative treatment modalities.6 In addition, prospective cohort study in Western Kenya indicated that the recurrence of at least 1 follow-up visit after the loop electrosurgical excision procedure (LEEP) was 13.0%,20 somewhat closer to our study finding. A single institutional experience also indicated that the relapse of locally advanced cervical cancer after radiochemotherapy was 23.0%.21 A review paper depicted that, the pooled prevalence of treatment failure to treat cervical lesions was 21.4% among women with HIV, and the prevalence of treatment failure using cryotherapy was 13.9%, which was closer to our current finding (15.7%).22

In this study, age greater or equal to 40 years was a significant predictor of the recurrence of the cervical precancer and our finding was similar to the study report of Peiretti et al,9 who reported the average age of the recurrence of cervical carcinoma is about 40-45 years. Low CD4 value mainly below
200 cells/mm³ was another significant predictor in the previous studies, though this was not the case in the current study. Although smoking caused invasive cervical cancer and precancer, the recurrence of cervical precancerous lesion due to smoking was not observed in our study. Our study indicated the lack of a significant difference between the recurrence of cervical precancerous lesion and contraceptive use, which was in concordance with a study that reported no association between cervical neoplasia and hormonal contraceptive use for birth control.

Even though various anticipated predictor variables for the recurrence were assessed in the present study only age greater 39 years, prolonged Corticosteroid use and abnormal pelvic examination were the major significant predictors of clinical importance. The implication of this finding might be due to the persistence of the infection and lesion residual at the old age of women, which means, older age was an independent predictor of the persistence and/or the recurrence. Patients with prolonged corticosteroid use developed cervical abnormalities, mainly due to decreased immune surveillance for tumor cells. The recurrence events occurred in the pelvic cavity.

**Strength and Limitation of the Study**

To the best of our knowledge, such kind of the study was not reported in Ethiopia yet. This study assessed average of 10 years screening and follow-up data and looked for the recurrence of cervical precancerous lesion after treatment, making it relevant to inform clinicians and care providers to manage their clients through understanding of the efficacy of cryotherapy which was among the strengths of the study. The limitations were, however, unknown HIV status of patients who were positive for cervical precancer screening and treated for cryotherapy in the register. The high loss to follow-up mainly on HIV negative women who were first time screening positive and treated for cryotherapy, and appointed for 1 year to revisit. This high loss to follow-up was a way to include less sample size in the analysis, and might have an impact on external validity of the study result. Missing data and improper documentation of the records were also some of the limitations in the study, which was always a challenge to conduct retrospective studies in such settings where documentation was not optimal.

**Conclusion**

Our findings indicated that cervical precancerous lesion recurrence after cryotherapy was higher than the expert review report of WHO guideline for use of cryotherapy (WHO 2011) with a higher proportion among HIV-negative women. The recurrence was greater among women of older age, and those who used corticosteroid. The time to recurrence was higher among HIV positive women than HIV negatives, probably due to lack of follow-up among HIV negative women. Further prospective cohort follow-up of women treated using cryotherapy and other treatment modality is recommended. In addition, local health authorities, including hospitals and other stakeholders need to establish a system to trace or manage loss to follow-up otherwise providing first visit treatment had no any guarantee whether the women were cured or not.

**Appendix**

**Abbreviations**

- ART: Antiretroviral therapy
- BMI: Body Mass Index
- CD4: Cluster of differentiation 4
- CI: Confidence interval
- CIN: Cervical intraepithelial neoplasia
- DF: Degree of freedom
- FIGO: The International Federation of Gynecology and Obstetrics
- HIV: Human Immunodeficiency virus
- HPV: Human papilloma virus
- HR: Hazard ratio
- IRB: Institutional review board
- LEEP: Loop electrosurgical excision procedure
- STI: Sexually transmitted infection
- VIA: Visual inspection with acetic acid

**Acknowledgments**

All the supervisors are duly acknowledged for their suggestion and advice during the research work. The authors extend gratitude to Addis Ababa University, Akilu Lemma Institute of Pathobiology, City Government of Addis Ababa Health Bureau, and St Paul’s Hospital Millennium Medical College for clearing the study. We extend our thanks to the Federal Ministry of Health (FMOH) in Ethiopia and Ethiopian Public Health Institute for writing a support letter to the responsible bodies including Regional Health Bureaus to conduct the study. The authors also acknowledge Ajanaw Yizengaw at Ethiopian Public Health Institute and Dr Achamelech (MD, GYN/OBS resident at Blacklion Medical School) for data collection and scientific input. Finally, all study participants and data collectors for their invaluable contribution during the study period.

**Author contributions**

AL designed the study, manage the overall activities from the inception of topic selection to data collection, data cleaning, analysis and writing draft manuscript. TT, JH, GMK, GM critically reviewed the manuscript, intellectual content, and add-up their valuable scientific input for the article.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval
Ethical approval for the study was obtained from Addis Ababa University, Aklilu Lemma Institute of Pathobiology, IRB (ALIPB-IRB/35/2013/21) and a further facility based ethical approval was obtained from the City Government of Addis Ababa Health Bureau (A/A/H/6092/227) and St. Paul’s Hospital, Millennium Medical College (SPHMMC-IRB/PW/23/398). The objectives of the study were well explained and permission was obtained from selected health facilities to collect data. No consent was taken for this particular study, since we conducted a chart review with no direct patient contact. All information obtained from chart review was kept confidential. Names or personal identifiers were not included in the study, meaning, all the patient details are de-identified. To trace back participant information, medical record number and serial number found in the eligible patient card was used.

Availability of data and materials
All data collected for this study were analyzed and included in this article, and data are available on reasonable request.

ORCID iDs
Agajie Likie Bogale https://orcid.org/0000-0002-2794-8251

References
1. World Health Organization. WHO Guidance Note: Comprehensive Cervical Cancer Prevention and Control: A Healthier Future for Girls and Women. World Health Organization; 2013. https://apps.who.int/iris/handle/10665/78128
2. RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008;16:41-49. doi:10.1016/S0968-8080(08)32415-X
3. Denny L, Anorlu R. Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev. 2012;21:1434-1438.
4. Echelman D, Feldman S. Management of Cervical Precancers: A Global Perspective. Hematol. Clin. 2012;26:31-44.
5. Einstein MH, Phaeton R. Issues in cervical cancer incidence and treatment in HIV. Curr Opin Oncol. 2010;22:449-455.
6. Oga EA, Brown JP, Brown C, Dareng E, Adekanmbi V, Oduotola M, et al. Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. BMC Wom Health. 2016;16:25. doi:10.1186/s12905-016-0304-8
7. Gadducci A, TanBJ, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncology Letters. 2010;1:3-11.
8. WHO Guidelines Use of Cryotherapy for Cervical Intra-epithelial Neoplasia, 2011.
9. Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow C, Maggioni A. Management of recurrent cervical cancer : A review of the literature. Surg Oncol. 2012;21:59-66.
10. Elit LM, Hírte H. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Rev Anticancer Ther. 2014;14:319-332.
11. Federal Democratic Republic of Ethiopia Ministry of Health. Guideline for Cervical Cancer Prevention and Control in Ethiopia; 2015.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577.
13. Addis Ababa City Administration Health Burea. Health-Sector Transformation Plan II HSTPII 2020-2024. 2021.
14. Sullivan KM, Soe MM. Sample Size for a Cross-Sectional, Cohort, or Clinical Trial Studies Sample Size for Cross-Sectional & Cohort Studies & Clinical Trials; 2007.
15. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention, WHO 2013, ISBN 978 92 4 154869 4.
16. WHO Guidelines for the Use of Thermal Ablation for Cervical Pre-cancer Lesions, Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
17. Taarnhøj GA, et al. Risk of Recurrence, Prognosis, and Follow-Up for Danish Women with Cervical Cancer in 2005-2013: A National Cohort Study. Cancer. 2018;124(5):943-951.
18. Hanprasertpong J, Jiamset I. Late Recurrence of Early Stage Cervical Cancer more than 3 Years after Radical Hysterectomy with Pelvic Node Dissection. Oncol Res Treat. 2017;40:1-7.
19. Tempfer CB, Beckmann W. State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer. Oncol Res Treat. 2016;39:525-533.
20. Huchko MJ, Leslie H, Maloba M, Zakaras J, Bukusi E, Cohen CR. Outcomes up to Twelve Months after Treatment with Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women. J Acquir Immune Defic Syndr. 2015;69:200-205. doi:10.1097/QAI.0000000000000565
21. Sasidharan A, Mahanthshetty UM, Gurram L, Chopra S, Engineer R, Maheshwari A, et al. Patterns of First Relapse and Outcome in Patients with Locally Advanced Cervical Cancer After Radiochemotherapy : A Single Institutional Experience. Indian J Gynecol. Oncol. 2020;18:1-6.
22. Debeaudrap P, Sobjngwi J, Tebeu PM, Clifford GM. Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus–infected Women: A Systematic Review and Meta-analysis of Treatment Failure. Clin Infect Dis. 2019;69(9):1555-1565.
23. Roura E, Castellsagu X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. *Int J Cancer.* 2014;135:453-466. VC 2013 UICC.

24. Ajah LO, Chigbu CO, Ozumba BC, Oguanuo TC, Ezeonu PO. Is there any association between hormonal contraceptives and cervical neoplasia in a poor Nigerian setting? *OncoTargets Ther.* 2015;8:1887-1892.

25. Chen J, Wang Z, Wang Z, Yang X. The risk factors of residual lesions and recurrence of the high-grade cervical intraepithelial lesions (HSIL) patients with positive-margin after conization. *Medicine.* 2018;97:41.

26. Zhu M, He Y, Zhou X, Qu Y, Sui L, Feng W, et al. Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study. *BMC Cancer.* 2015;15:744. doi:10.1186/s12885-015-1748-1

27. Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. *Inflamm Bowel Dis.* 2019;25(6):998-1005.

28. Chao X, Fan J, Song X, You Y, Wu H, Wu M, et al. Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study. *Front Oncol.* 2020;10:591253. doi:10.3389/fonc.2020.591253